arrow
S

Stefano Tamberi

ausl romagna
H指数:35
被引数:5,216

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real-world study

胆道癌患者接受化疗免疫疗法后的预后分层:一项回顾性多中心真实世界研究

Cancer
IF5.1
2026-09-160
PRE
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab

探索系统性治疗后的手术治疗在局部晚期胆道癌中的作用:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的大型回顾性跨国真实世界队列的结局

2026-08-150
PRE
The Effect of Metformin on Atezolizumab/Bevacizumab Treatment in Patients with Carcinoma and Diabetes

二甲双胍对接受阿替利珠单抗/贝伐珠单抗治疗的癌病患者的影响

2026-01-010
PRE
Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial

高级别子宫内膜癌中的同源重组修复状态:来自随机、II期MITOEND 3试验的探索性生物标志物分析

2025-12-050
OAAI
A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study

一项关于吉西他滨和 Nab-Paclitaxel 作为换用维持治疗 versus 改良 FOLFIRINOX 作为一线化疗在晚期胰腺癌患者中的随机 III 期临床试验:PANThEON 研究

2025-11-280
PRE
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers

度伐利尤单抗在晚期胆道癌中的应用:来自多个国际中心大型患者队列的真实世界数据

2025-11-120
OAAI
Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: a secondary endpoint of the ARMANI phase 3 trial

帕克他赛和雷莫芦单抗序贯维持治疗在晚期胃肠癌中的患者报告结局:ARMANI III期试验的次要终点

2025-10-200
PRE
Genomic Pathway Alterations and Their Prognostic Impact in Biliary Tract Cancer: Insights from a Multinational Cohort Treated with Cisplatin, Gemcitabine, and Durvalumab

基因组通路改变及其在胆道癌中的预后影响:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的跨国队列的见解

2025-10-030
PRE
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial

基因组匹配疗法在晚期实体瘤中的应用:随机II期ROME试验

2025-09-290
OAAI
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population

接受顺铂、吉西他滨和度伐利尤单抗治疗的晚期胆道癌患者中分子改变的影响:一项大型、真实世界、全球性人群研究

2025-09-011
PRE
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset

pT4N0结肠癌的预后影响与临床管理:来自大型、多中心、国际、真实世界数据集的数据

2025-07-150
OAAI
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial
2025-04-080
OAAI
Impact of edoxaban-related adverse events in patients with cancer experiencing venous thromboembolism during antineoplastic therapy: Results of the phase IV EDOI study (GOIRC-05-2018)

奥德沙班相关不良事件对接受抗肿瘤治疗并发静脉血栓栓塞的癌症患者的影响:EDOI研究(GOIRC-05-2018)IV期研究结果

2025-03-010
OAAI
Homologous Recombination Repair Status In Advanced Endometrial Cancer. An Exploratory Biomarker Analysis From The Randomized, Phase II MITO END 3 Trial

高级子宫内膜癌的同源重组修复状态。来自随机、II期MITO END 3试验的探索性生物标志物分析

2025-02-010
PRE
Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study

绝经前激素受体阳性早期乳腺癌患者的辅助内分泌治疗选择: 来自前瞻性GIM23-POSTER研究的见解

BREAST
IF7.9
2024-10-011
OAAI
EXcellenT (exercise in extended oncogene addicted lung cancer in active treatment) trial: Preliminary results on impact of physical activity (PA) on emotional, metabolic and immune status

EXcellenT(针对活跃治疗中扩展性致癌基因依赖性肺癌的运动试验)研究:关于身体活动(PA)对情绪、代谢和免疫状态影响的初步结果

2024-09-010
PRE
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population

Durvalumab联合吉西他滨和顺铂治疗晚期胆道癌: 大量现实世界人口

2024-09-013
PRE
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas
2024-09-012
OAAI